Early Phase Allergic Response After Treatment With Study Drug in Active and Placebo Patients Week 8, Week 16 [clinicaltrials_resource:92bf5643445785289841504c18070f4d]
The EAR was defined as the maximum percent drop in forced expiratory volume in one second (FEV1) in the first 30 minutes after the challenge:
EAR = 100* [ FEV1 (0) - Minimum FEV1 (10, 15, 30 min)] / FEV1 (0). For FEV1 (0), the "best post saline (Control) FEV1" was used. The EAR was analyzed using a linear (ANCOVA) model with a fixed effect for treatment groups and the EAR from the baseline challenge was used as a covariate.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Early Phase Allergic Response After Treatment With Study Drug in Active and Placebo Patients Week 8, Week 16 [clinicaltrials_resource:92bf5643445785289841504c18070f4d]
The EAR was defined as the maximum percent drop in forced expiratory volume in one second (FEV1) in the first 30 minutes after the challenge:
EAR = 100* [ FEV1 (0) - Minimum FEV1 (10, 15, 30 min)] / FEV1 (0). For FEV1 (0), the "best post saline (Control) FEV1" was used. The EAR was analyzed using a linear (ANCOVA) model with a fixed effect for treatment groups and the EAR from the baseline challenge was used as a covariate.
Bio2RDF identifier
92bf5643445785289841504c18070f4d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:92bf5643445785289841504c18070f4d
measure [clinicaltrials_vocabulary:measure]
Early Phase Allergic Response ...... in Active and Placebo Patients
time frame [clinicaltrials_vocabulary:time-frame]
Week 8, Week 16
description
The EAR was defined as the max ...... lenge was used as a covariate.
identifier
clinicaltrials_resource:92bf5643445785289841504c18070f4d
title
Early Phase Allergic Response ...... acebo Patients Week 8, Week 16
@en
type
label
Early Phase Allergic Response ...... f5643445785289841504c18070f4d]
@en